Ductal Carcinoma In Situ (DCIS) Clinical Trials

A listing of Ductal Carcinoma In Situ (DCIS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 76 clinical trials
Featured trial
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

  • 344 views
  • 08 Nov, 2020
  • 1 location
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

carcinoma in situ (DCIS) patients, the aforementioned two studies included a proportional patients who had young age and negative estrogen receptor (ER) status tumor. Previous studies and our studies

estrogen
radiotherapy to breast
breast cancer
breast-conserving surgery
breast tumor
  • 18 views
  • 14 Feb, 2022
  • 1 location
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial (COMET)

is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferior cancer or quality of life outcomes compared to surgery.

HER2
endocrine therapy
erbb2
invasive cancer
mastectomy
  • 1343 views
  • 16 Oct, 2022
  • 118 locations
Well-Being After Breast Cancer Surgery (WB ABCs)

breast surgery for lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer, and to examine the roles of psychological and physiological variables as modifiable

  • 0 views
  • 07 Jul, 2022
  • 2 locations
Management of Low-risk (Grade I and II) DCIS (LORD)

A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-risk DCIS (grade I and II). This implies that many women might be unnecessarily going through intensive treatment resulting in a decrease in quality of life and an increase in health care costs, …

HER2
erbb2
digital mammography
mastectomy
estrogen
  • 464 views
  • 04 Jun, 2022
  • 51 locations
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with …

methotrexate
breast cancer
carboplatin
doxorubicin
trastuzumab
  • 29 views
  • 03 Jun, 2022
  • 17 locations
Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

This trial studies the effect of an electronic health (eHealth) support program called PACK Health on patient reported health outcomes in patients with breast cancer. PACK Health monitors breast cancer patients' reported side effects and experience of care when receiving chemotherapy. Participating in the PACK Health coaching program may improve …

invasive breast cancer
carcinoma
carcinoma in situ
cancer
ductal carcinoma in situ
  • 4 views
  • 12 Jul, 2022
  • 1 location
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast (ROMANCE)

Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in

HER2
erbb2
lobular carcinoma
ki-67
growth factor
  • 52 views
  • 04 Oct, 2022
  • 28 locations
Women Informed to Screen Depending on Measures of Risk (Wisdom Study) (WISDOM)

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but …

Accepts healthy volunteers
cancer
breast cancer
mammogram
  • 79 views
  • 26 Jan, 2022
  • 10 locations
Approaches to Identify and Care for Individuals With Inherited Cancer Syndromes

This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad, public-wide testing for high risk cancer types (like hereditary breast and …

BRCA1
ductal carcinoma in situ
breast cancer
genetic testing
primary cancer
  • 21 views
  • 14 Oct, 2022
  • 2 locations